| BRISTOL-MYERS SQUIBB COMPANY Patent applications |
| Patent application number | Title | Published |
|---|
| 20120101262 | PROTEIN PURIFICATION BY CAPRYLIC ACID (OCTANOIC ACID) PRECIPITATION - The invention provides methods for a purifying protein of interest from a mixture comprising the protein of interest and one or more contaminants, including host cell DNA and proteins, by precipitation of the contaminants with caprylic acid. Such methods are particularly useful for purifying antibodies from cell cultures. Moreover, mixtures that have been depleted of contaminants using the methods of the invention can be used directly in downstream chromatography applications (e.g., ion exchange chromatography) without any further purification. These methods lead to manufacturing processes with a minimum number of unit operations and reduce the resource requirements, and thus positively influence the cost of goods for therapeutic protein production. | 04-26-2012 |
| 20120087978 | DOSAGE FORMS OF APIXABAN - The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form. | 04-12-2012 |
| 20120071403 | Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof - The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided. | 03-22-2012 |
| 20120046271 | 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin - The compounds of the present invention are represented by the following 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives having formula (I): | 02-23-2012 |
| 20120035177 | TABLET FORMULATION FOR P38 INHIBITOR AND METHOD - A tablet formulation is provided which includes a medicament which is a pharmaceutically acceptable salt of a p38 inhibitor, such as the p38 HCl salt of the structure Formula (I) and which has good physical stability when stored at up to 25 C./60% RH in closed containers with desiccant. The tablet formulation will contain crospovidone as a tablet disintegrant, which, unlike croscarmellose sodium, will not cause disproportionation of the HCl salt to the free base of P38 inhibitor and thus will have acceptable dissolution properties even after storage at room temperature. | 02-09-2012 |
| 20120027782 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) - The present disclosure relates to antibody-partner molecule conjugates directed to PTK7. Also described are methods for treating or preventing a disease characterized by growth of tumor cells expressing PTK7 using the antibody-partner molecule conjugates. | 02-02-2012 |
| 20120022041 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - Disclosed are compounds of Formula (I) | 01-26-2012 |
| 20120021533 | SENSITIVE METHOD TO ANALYSE FREE PEG-MALEIMIDE - The present invention relates generally to a novel method using HPLC and fluorescence detection of free PEG-mal in PEGylated proteins and PEG-mal raw materials by adding a fluorescent label to the free PEG-mal. | 01-26-2012 |
| 20110305663 | SERUM ALBUMIN BINDING MOLECULES - The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain ( | 12-15-2011 |
| 20110263548 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS - Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R | 10-27-2011 |
| 20110262448 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 10-27-2011 |
| 20110257085 | Crystal Forms of Saxagliptin and Processes for Preparing Same - Physical crystal structures of a compound of the formula I: | 10-20-2011 |
| 20110224199 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues - Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I | 09-15-2011 |
| 20110212930 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS - The present application describes lactam-containing compounds and derivatives thereof of Formula I: | 09-01-2011 |
| 20110201795 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors - Method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases. and intermediates thereof. The C-aryl glucosides may be complexed with amino acid complex forming reagents. | 08-18-2011 |
| 20110200672 | COATED TABLET FORMULATION AND METHOD - A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin | 08-18-2011 |
| 20110172176 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME - The present invention relates to physical crystal structures of a compound of the formula I: | 07-14-2011 |
| 20110166154 | IDENTIFICATION OF PREDICTIVE MARKERS OF RESPONSE TO DASATINIB IN HUMAN COLON CANCER - Methods and compositions are provided useful in the diagnosis, treatment and management of cancers wherein cancer cells express certain polynucleotides and/or polypeptides that are differentially expressed in colon cancer subtypes that are sensitive to therapy with abl kinase inhibitors and src kinase inhibitors. In particular, PTK-7, PLK-2 and PLK-3 could be identified as markers for determining the responsiveness of cancer to dasatinib. | 07-07-2011 |
| 20110152340 | Methods for Identifying Subjects With an Increased Likelihood of Responding to DPP-IV Inhibitors - The invention provides novel in vitro diagnostic methods for identifying subjects or patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments which comprise at least one polymorphic locus, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the invention are useful in phenotype correlations, medicine, and genetic analysis. | 06-23-2011 |
| 20110077214 | METHOD FOR TREATING HYPONATREMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME - Methods are provided for treating hyponatremia, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with a diuretic agent. Additionally, compositions comprising an SGLT2 inhibitor optionally with a supply of carbohydrate, and/or a combination of an SGLT2 inhibitor and a diuretic agent are provided in the instant invention and are provided for use in the inventive methods. | 03-31-2011 |
| 20110077213 | METHOD FOR TREATING AND PREVENTING KIDNEY STONES EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME - Methods are provided for treating and/or preventing kidney stones, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with a diuretic agent. Additionally, compositions comprising an SGLT2 inhibitor, optionally with a supply of carbohydrate, and/or a combination of an SGLT2 inhibitor and a diuretic agent are provided in the instant invention and are provided for use in the inventive methods. | 03-31-2011 |
| 20110071288 | INTERMEDIATE USEFUL IN PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS AND A PROCESS FOR MAKING THE INTERMEDIATE - The invention relates to 2,4-dibromoropyrrolo[1,2-f][1,2,4]triazine, which is an intermediate useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and a process for preparing the intermediate. | 03-24-2011 |
| 20110065658 | METHOD FOR TREATING HYPERURICEMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME - Methods are provided for treating hyperuricemia, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with an inhibitor of uric acid synthesis. Additionally, pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate or an inhibitor of uric acid synthesis or a supply of carbohydrate and an inhibitor of uric acid synthesis are provided in the instant invention and are provided for use in the inventive methods. | 03-17-2011 |
| 20110064801 | Pharmaceutical Formulations Containing an SGLT2 Inhibitor - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate | 03-17-2011 |
| 20110053842 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS THAT BIND EGFR - The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 03-03-2011 |
| 20110034506 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS DGAT1 INHIBITORS - Disclosed are triazolopyridine compounds of the following Formula (I); or stereoisomers or salts thereof. Also, disclosed are methods of using the compound in the treatment of obesity, dyslipidemia, diabetes and atherosclerosis, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof. | 02-10-2011 |
| 20110034384 | COMBINATION VEGFR2 THERAPY WITH mTOR INHIBITORS - The present disclosure relates to improved methods of treating neoplastic disorders by combining VEGFR2 specific inhibitor treatment with mTOR inhibitors. The present disclosure also relates to methods of preventing the development of VEGFR2 resistance. | 02-10-2011 |
| 20110020797 | Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors - The invention provides novel in vitro diagnostic methods for identifying patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides, which comprise at least one polymorphic locus per fragment, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis. | 01-27-2011 |
| 20110020277 | Dioxolane and Dioxolanone Fused Indolobenzadiazepine HCV NS5B Inhibitors - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. I | 01-27-2011 |
| 20110015141 | METHOD FOR TREATING CANCERS HAVING HIGH GLUCOSE REQUIREMENTS EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF - Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent. | 01-20-2011 |
| 20100323994 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS - The invention provides compounds of formula I | 12-23-2010 |
| 20100310549 | INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS - The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides. | 12-09-2010 |
| 20100305114 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues - Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I | 12-02-2010 |
| 20100291642 | Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor - A process for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV is provided which employs a BOC-protected amine of the structure | 11-18-2010 |
| 20100285000 | USE OF VEGFR-2 INHIBITORS FOR TREATING METASTATIC CANCER - The present application provides compositions and methods for treating metastatic cancer. Patients having or at risk of developing metastases may be treated. Compositions useful for the invention include VEGFR-2 specific inhibitors. | 11-11-2010 |
| 20100274025 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF - Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided. | 10-28-2010 |
| 20100261886 | PROTEIN PURIFICATION BY CITRATE PRECIPITATION - The invention provides methods for isolating proteins in purified form from mixtures by precipitation with citrate. The methods are advantageous in that they effectively separate a protein from lower molecular weight contaminants, including fragments or portions of the protein. Such methods are particularly useful for purifying antibodies from mixtures containing antibody proteolytic fragments and unpaired chains. | 10-14-2010 |
| 20100234381 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 MODULATORS - A method for predicting the likelihood a mammal will respond therapeutically to a method of treating cancer comprising administering a VEGFR-2 modulator or a dual VEGFR-2/FGFR-1 modulator wherein the method comprises: (a) measuring in the mammal the level of FGF2; (b) either comparing the level of FGF2 in the sample relative to a standard to permit assignment of the sample to either being a member of an FGF2 positive class or an FGF2 negative class, or comparing the level of FGF2 in the sample relative to a standard, wherein assignment of the mammal to the FGF2 positive sample class or a determination that the mammal has an elevated level of FGF2, indicates an increased likelihood the patient will respond therapeutically to the cancer treatment. Methods of predicting whether a mammal has received an efficacious dose of a VEGFR-2 modulator or a dual VEGFR-2/FGFR-1 modulator is also disclosed, in addition to kits comprising these methods. | 09-16-2010 |
| 20100221754 | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators - EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer. | 09-02-2010 |
| 20100210624 | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN - The aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepine derivative compounds of the present invention are represented by formulae (I) (A-E) having the following structure where the carbon atom designated * is in the R or S configuration and the substituents X and R | 08-19-2010 |
| 20100210511 | Combination VEGFR2 Therapy with Temozolomide - The present disclosure relates to improved methods of treating neoplastic disorders by combining VEGFR2 specific inhibitor treatment with temozolomide. In particular, methods for treating glioblastoma with a combination of a VEGFR2 inhibitor and temozolomide are provided. | 08-19-2010 |
| 20100179094 | BISPECIFIC EGFR/IGFIR BINDING MOLECULES - The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain. | 07-15-2010 |
| 20100144599 | VEGF PATHWAY BLOCKADE - The present invention relates to innovative proteins that block the VEGF-VEGFR pathway mediated biology and pathology, as well as pharmaceutical formulations of these proteins. The invention also relates to dosage therapies for the administration of these proteins. The invention further relates to the use of VEGF-A as a biomarker for determining an effective dosage and predicting the efficacy of these proteins. | 06-10-2010 |
| 20100137287 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN - The aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepine derivative compounds of the present invention are represented by formulae 1(A-D) having the following structure: where the substituents X and R | 06-03-2010 |
| 20100121033 | TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR - The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. | 05-13-2010 |
| 20100119510 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS - The present application describes lactam-containing compounds and derivatives thereof of Formula I: | 05-13-2010 |
| 20100114045 | OSTOMY POUCH APPLIANE - An ostomy appliance comprises an ostomy pouch having front wall, a rear wall with a stomal aperture, and an adhesive body fitment secured or securable around the stomal aperture. At least a portion of the adhesive of the body fitment is moldable. The front wall of the pouch comprises an access aperture providing access through the pouch interior for molding the adhesive. The access aperture is closable by a closure panel attachable over said access aperture by a peelable/resealable adhesive. | 05-06-2010 |
| 20100113454 | PYRROLOTRIAZINE KINASE INHIBITORS - The invention provides compounds of formula I | 05-06-2010 |
| 20100048581 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS - The invention provides compounds of formula I [INSERT CHEMICAL STRUCTURE HERE] (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease. | 02-25-2010 |
| 20100041717 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES - Compounds of formula (Ia) and (Ib), wherein A, B, C, R | 02-18-2010 |
| 20100041636 | NOVEL KINASE INHIBITORS - The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. | 02-18-2010 |
| 20100028354 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE - Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual. | 02-04-2010 |
| 20100016233 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues - Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I | 01-21-2010 |
| 20100015208 | ANTIBACTERIAL WOUND DRESSING - The present invention relates to wound dressings, in particular to an antibacterial wound dressing based on silvered gel-forming fabric and to a process for the manufacture of such a wound dressing. | 01-21-2010 |
| 20090326496 | TRANSPARENT HYDROGEL WOUND DRESSING - A wound dressing comprising a hydrogel polymer in sheet form reinforced with a fabric comprising gel-forming fibres which fabric is capable of absorbing exudate to allow the wound to be viewed through the dressing. | 12-31-2009 |
| 20090324625 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues - Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I | 12-31-2009 |
| 20090299040 | MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS - The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 12-03-2009 |
| 20090291913 | FACTOR Xa INHIBITOR FORMULATION AND METHOD - An injectable Factor Xa inhibitor formulation is provided which includes the Factor Xa inhibitor razaxaban or apixaban, a solubilizing agent which is a substituted β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBE-CD) or hydroxypropyl-β-cyclodextrin (HPB-CD), and water. A method for preventing or treating venous thrombosis, deep venous thrombosis and acute coronary syndrome employing the above formulation is also provided. | 11-26-2009 |
| 20090215792 | METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA CELLS - Here, the inventors disclose the treatment of imatinib mesylate resistant chronic myelogenous leukemia cells with a cotreatment of vorinostat (SAHA, suberoylanilide hydroxamic acid) and dasatinib, a dual Abl/Src kinase (TK) inhibitor. Combined treatment of cultured human CML and BaF3 cells with vorinostat and dasatinib induced more apoptosis than either agent alone, as well as synergistically induced loss of clonogenic survival, which was associated with greater depletion of Bcr-Abl, p-CrkL and p-STAT5 levels. Co-treatment with dasatinib and vorinostat also attenuated the levels of Bcr-AblE255K and Bcr-AblT315I and induced apoptosis of BaF3 cells with ectopic expression of the mutant forms of Bcr-Abl. Finally, co-treatment of the primary CML cells with vorinostat and dasatinib induced more loss of cell viability and depleted Bcr-Abl or Bcr-AblT315I, p-STAT5 and p-CrkL levels than either agent alone. | 08-27-2009 |
| 20090177135 | WOUND DRESSING - The present invention relates to a wound dressing and in particular a wound dressing for application to the sacrum of a patient. The wound dressing is an absorbent pad having one or more lines about which the dressing can fold. | 07-09-2009 |
| 20090176758 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS - The present application describes lactam-containing compounds and derivatives thereof of Formula I: | 07-09-2009 |
| 20090118260 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN - The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): | 05-07-2009 |
| 20090082743 | POUCH FOR COLLECTING HUMAN BODY WASTE AND DRAINAGE ADAPTER THEREFOR - A drainable urine pouch includes a discharge portion that is foldable between a discharge position and a closed position. A security flap is sealed to both walls of the pouch by a through weld, to define a baffle near the discharge portion. The discharge portion includes a constriction, and a stepped profile with multiple step stages. The discharge portion has one or more bias members. A drainage adapter is releasably coupled to the discharge portion. The drainage adapter has a plug with a shoulder for abutting the constriction in the discharge portion, to locate the adapter correctly for obtaining a liquid-tight seal. | 03-26-2009 |
| 20090036438 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS - The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): | 02-05-2009 |
| 20090030203 | PREPARATION OF 2-AMINO-THIAZOLE-5-CARBOXYLIC-ACID DERIVATIVES - A method for preparing a compound of the structure I, | 01-29-2009 |
| 20090018311 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF - Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided. | 01-15-2009 |
| 20080280905 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS - The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y | 11-13-2008 |
| 20080275009 | ORAL ADMINISTRATION OF N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-1,3-THIAZOLE-5-CARBOXAMIDE AND SALTS THEREOF - Disclosed are a method of treating cancer and/or other proliferative diseases comprising orally administering N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof, and pharmaceutical compositions comprising N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof. Also disclosed are N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide salts, as well as crystalline forms thereof. | 11-06-2008 |
| 20080269698 | OSTOMY APPLIANCE COLLECTOR - An ostomy appliance comprising a collection device for collecting body waste. At least a portion of the collection device is thermoformed from a sheet of plastics material, e.g., vacuum formed or pressure formed. The collection device may be configurable between a compact, stowed condition and an expanded deployed condition. The thermoformed portion is thermoformed in the deployed condition. The collection device has a depth:diamater ratio of at least 1:1. The ostomy appliance is a controlled evacuation appliance, or a collection pouch. | 10-30-2008 |
| 20080269499 | CRYSTALLINE FORMS AND PROCESS FOR PREPARING SPIRO-HYDANTOIN COMPOUNDS - A process is provided for preparing spiro-hydantoin compounds of the formula II | 10-30-2008 |
| 20080221135 | COMBINATION THERAPY - This invention relates to a combination of anti-cancer compounds which comprises a) an orally effective taxane, and b) a thymidylate synthase inhibitor, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use. | 09-11-2008 |
